Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 2
1996 1
1997 1
1998 2
1999 2
2009 4
2011 4
2012 1
2013 3
2014 6
2015 11
2016 12
2017 6
2018 10
2019 8
2020 7
2021 10
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Self-regulation predicts companionship in children with autism.
Nuske HJ, Shih WI, Sparapani N, Baczewski L, Dimachkie Nunnally A, Hochheimer S, Garcia C, Castellon F, Levato L, Fischer E, Atkinson-Diaz ZL, Li J, Mandell DS, Kasari C; Autism Intervention Research—Behavioral 1 team. Nuske HJ, et al. Among authors: levato l. Int J Dev Disabil. 2021 Sep 27;68(6):889-899. doi: 10.1080/20473869.2021.1917109. eCollection 2022. Int J Dev Disabil. 2021. PMID: 36568619 Free PMC article.
A review of atomoxetine effects in young people with developmental disabilities.
Aman MG, Smith T, Arnold LE, Corbett-Dick P, Tumuluru R, Hollway JA, Hyman SL, Mendoza-Burcham M, Pan X, Mruzek DW, Lecavalier L, Levato L, Silverman LB, Handen B. Aman MG, et al. Among authors: levato l. Res Dev Disabil. 2014 Jun;35(6):1412-24. doi: 10.1016/j.ridd.2014.03.006. Epub 2014 Apr 16. Res Dev Disabil. 2014. PMID: 24732041 Free PMC article. Review.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: levato l. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
83 results